Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops

Sponsor
Sheba Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT03220490
Collaborator
(none)
65
Enrollment
1
Location
4
Arms
60
Anticipated Duration (Months)
1.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

According to the American Academy of Ophthalmology's Preferred Practice Pattern on Primary Open Angle Glaucoma, patients should wait five minutes between administering topical drops for intra-ocular pressure reduction.

To date, no study has shown the efficacy of this waiting period. In this study, we aim to establish the clinical significance of keeping a time interval between glaucoma medications.

Condition or DiseaseIntervention/TreatmentPhase
  • Behavioral: 5 minute interval between regular glaucoma drops - Long term
  • Behavioral: no interval between regular glaucoma drops - Long term
  • Drug: IOP reduction of Brimonidine and Timolol with time interval
  • Drug: IOP reduction of Brimonidine and Timolol no time interval
N/A

Detailed Description

Glaucoma is a chronic disease in which constant damage to retinal nerve fibers. In most cases the damage is caused by increased intra-ocular pressure (IOP). Without treatment, this disease can cause irreversible decrease in visual fields until the patient eventually becomes blind.

The first line of treatment include topical eye-drops aimed at reducing IOP. Many patients require more than one drug type.

According to the American Academy of Ophthalmology's Preferred Practice Pattern on Primary Open Angle Glaucoma, patients who are using two or more drop types, should wait five minutes after the first drop, before administering the second type..

To date, no study has shown the efficacy of this waiting period. In this study, we aim to establish the clinical significance of keeping a time interval between glaucoma medications.

The study composes of two separate parts:

Part 1 - The aim of this part will be to estimate the short term effect on IOP reduction. Healthy subjects willing to participate voluntarily, will be given two IOP reduction drugs (Tilopitc and Alphagan) at different intervals in each eye. After which they will undergo repeated IOP measurements over a course of 7 hours.

Part 2 - The aim of this part will be to estimate the short term effect on IOP reduction. Glaucoma patients treated in the glaucoma clinic at Sheba-Medical center who are taking two different types of IOP reduction drugs in both eyes, will be recruited. The patients will be asked to keep a constant 5 minute interval between drops in one eye and to instill the drops in the other eye with no waiting time. After one month the patients will return for a revaluation of IOP and then be asked to switch the eyes so that the eye in which the interval was not kept will now be the one in which the drop will be put after 5 minute interval.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
65 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops
Actual Study Start Date :
Nov 1, 2017
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Experimental: Short term: interval no-interval eye

On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with a 5 minutes interval between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment. On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol no time interval. Again one drop of the same two types of drugs will be given at the same order but with no time interval between them. IOP measurements will be taken in the same manner as on the first day.

Drug: IOP reduction of Brimonidine and Timolol with time interval
In the selected eye the subject will be given two types of IOP reduction drops: first "Brimonidine", "Alphagan®" (an alpha-agonist) followed by "Timolol", "Tiloptic®" (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop.
Other Names:
  • Short - interval
  • Drug: IOP reduction of Brimonidine and Timolol no time interval
    In the selected eye the subject will be given two types of IOP reduction drops:first "Brimonidine", "Alphagan®" (an alpha-agonist) followed by "Timolol", "Tiloptic®" (a beta-blocker). The drops will be given one after the other with no waiting period.
    Other Names:
  • Short - no interval
  • Experimental: Short term: No-interval interval eye

    On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with no waiting period between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment. On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. Again one drop of the same two drugs will be given at the same order but with a five minute time interval between the first and second drop. IOP measurements will be taken in the same manner.

    Drug: IOP reduction of Brimonidine and Timolol with time interval
    In the selected eye the subject will be given two types of IOP reduction drops: first "Brimonidine", "Alphagan®" (an alpha-agonist) followed by "Timolol", "Tiloptic®" (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop.
    Other Names:
  • Short - interval
  • Drug: IOP reduction of Brimonidine and Timolol no time interval
    In the selected eye the subject will be given two types of IOP reduction drops:first "Brimonidine", "Alphagan®" (an alpha-agonist) followed by "Timolol", "Tiloptic®" (a beta-blocker). The drops will be given one after the other with no waiting period.
    Other Names:
  • Short - no interval
  • Experimental: Long term: interval no-interval eye

    In the first phase the effect of 5 minute interval between regular glaucoma drops - long term will be examined. The patients will be asked in this eye to wait 5 minutes after taking one of their IOP reduction drugs, before instilling the second type for a total duration of 1 month. After the one month has passed IOP measurement will be taken and the patients will be asked to switch to the no interval between regular glaucoma drops - long term phase in which they will be asked to take the drops for this eye at the same order but with no waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated.

    Behavioral: 5 minute interval between regular glaucoma drops - Long term
    In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
    Other Names:
  • Long - interval
  • Behavioral: no interval between regular glaucoma drops - Long term
    In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
    Other Names:
  • Long - no interval
  • Experimental: Long term: No-interval interval eye

    In the first phase no interval between regular glaucoma drops - Long term will be examined. The patients will be asked in this eye to take both IOP reduction drugs, with no waiting period between them for a total duration of 1 month. After the one month has passed IOP measurement will be taken and the patient will be asked to switch to the to 5 minute interval between regular glaucoma drops - Long term phase and take the drops for the same eye at the same order but with a five minute waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated.

    Behavioral: 5 minute interval between regular glaucoma drops - Long term
    In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
    Other Names:
  • Long - interval
  • Behavioral: no interval between regular glaucoma drops - Long term
    In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
    Other Names:
  • Long - no interval
  • Outcome Measures

    Primary Outcome Measures

    1. Acute group - difference in IOP reduction [Six hour after taking the drops]

      Difference in IOP change from baseline between the two eyes after treatment

    2. Chronic group - change in IOP [one month]

      Difference between eye in IOP change from baseline after intervention

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Short duration group

    • Healthy individuals with negative past ocular history

    • able to give consent

    Long duration group:
    • Diagnosed with primary open angle glaucoma and being treated with two types of IOP reduction drops.

    • No other medical ocular history.

    • No cognitive disfunction

    • able to give consent

    • No known arrhythmia

    Exclusion Criteria (Both groups):
    • Corneal disease preventing from visualization of the angle

    • Closed angle

    • Pregnant women

    • Previous ocular surgery (including cataract or refractive surgery)

    • Known allergy to ocular drops used in this study (e.g. brimonidine, timolol)

    • History of asthma or arrhythmia

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Sheba Medical CenterTel HaShomerIsrael

    Sponsors and Collaborators

    • Sheba Medical Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sheba Medical Center
    ClinicalTrials.gov Identifier:
    NCT03220490
    Other Study ID Numbers:
    • SHEBA-17-3820-AL-CTIL
    First Posted:
    Jul 18, 2017
    Last Update Posted:
    Oct 4, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 4, 2021